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Several  antigen-nonspecific,  genetically  unrestricted  factors derived from  T 
cells have been shown to play a  role in the regulation of B cell responses (1-9). 
One such factor, designated B cell growth factor (BCGF-1  or BSF-1), ~ appears 
to be required  for the proliferation  of a  subset of B cells after interaction  with 
antigen  or antiimmunoglobulin  molecules.  A  second series of factors, called B 
cell differentiation (BCDF) or T  cell-replacing factors (TRF), is involved in the 
terminal maturation of proliferating B cells into immunoglobulin-secreting cells. 
There has been controversy regarding the possible involvement of T  cell growth 
factor or interleukin  2  (IL-2) in  B cell responses and  specifically the ability of 
this growth factor to act directly on B lymphocytes. The proponents of a direct 
action  of  IL-2  on  B  cells  showed  that  depletion  of IL-2  from  cofactor-rich 
supernatants by absorption on IL-2-dependent T  cell lines also removed a factor 
required  for  B  cell  differentiation  (4,  5,  10).  Furthermore,  there  was a  strict 
correlation  between  the  levels  of IL-2  and  one  of the  B  cell-specific factors 
required for antibody production (4). This view that IL-2 acts directly on B cells 
has been challenged, since both mouse and human IL-2 have been distinguished 
from  B  cell  growth  and  differentiation  factors  (7-11).  The  IL-2-containing 
supernatants generally used in the previous studies (the supernatant of the FS6- 
14.13 line) also contained BCGF and one or more TRFs (9).  Furthermore,  IL-2 
was not absorbed from cofactor-rich supernatants  by incubation  with  lipopoly- 
saccharide (LPS)-stimulated splenic lymphoblasts (4).  Finally, radiolabeled IL-2 
did not bind to LPS-stimulated B cells or to either of the two Burkitt's lymphoma 
B cell lines examined  (Raji and  Daudi) suggesting that  B cells do not manifest 
receptors for IL-2 (12). 
We have reexplored the possibility that certain activated B cells display recep- 
tors for IL-2 using the anti-Tac monoclonal antibody produced in our laboratory 
(13, 14). This monoclonal antibody identifies the human membrane receptor for 
IL-2 (15,  16,  17). The observations that led to this conclusion include: (a) anti- 
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Tac blocks the proliferation of IL-2-dependent T  cell lines, but does not affect 
the proliferation of IL-2-independent T  cell lines; (b) anti-Tac blocks the binding 
of radiolabeled  IL-2  to  its  specific receptor on activated T  cells; and  (c)  IL-2 
blocks the binding of radiolabeled anti-Tac to its antigenic target on activated T 
cells and T  cell lines. Furthermore,  all membrane-associated,  IL-2-binding mol- 
ecules were removed by passage through an anti-Tac Sepharose column and, in 
parallel studies, all molecules that bound to an anti-Tac Sepharose column were 
removed by prior passage through  an  IL-2 Affigel affinity support (16).  Thus, 
under the conditions examined, all anti-Tac-reactive molecules appeared capable 
of binding IL-2 and the ability to bind IL-2 was limited to the Tac protein. 
Previously (17,  18), we made two observations using the monoclonal anti-Tac 
that suggested that  IL-2 might play a  role in B cell maturation.  First, anti-Tac 
inhibited the maturation of B cells into immunoglobulin-secreting  cells as mea- 
sured in a  reverse hemolytic plaque assay when peripheral  blood mononuclear 
cells were stimulated with pokeweed mitogen (PWM) (17). Secondly, virtually all 
hairy cell leukemic populations that were demonstrated to be B cells on the basis 
of immunoglobulin  gene rearrangements  displayed the Tac antigen  on the cell 
surface (18). 
In the present study we demonstrate that, while normal resting B cells are Tac 
antigen  negative,  these cells can be activated to express the Tac antigen.  Fur- 
thermore,  we  demonstrate  that  certain  leukemic  B  cell  populations  are  Tac 
antigen positive.  In addition,  cloned lines of normal,  Epstein-Barr virus (EBV)- 
transformed  B  cells display  the  Tac  antigen  and  high  affinity  IL-2  receptors 
detected with radiolabeled IL-2. We also demonstrate that the receptor identified 
by anti-Tac on activated B cells is similar in size (Mr 55,000) to the IL-2 receptor 
present  on activated T  cells.  Finally using a  Tac-positive cloned normal  B cell 
line, we demonstrate that purified IL-2 is capable of amplifying the level of Tac 
antigen expression and inducing augmented immunoglobulin production. Thus, 
IL-2 receptor expression does not appear to be confined to cells of the T  cell 
lineage, but can also be induced on normal B lymphocytes. 
Materials and Methods 
Cells Analyzed for IL-2 Receptor Expression.  Purified B cells prepared from heparinized 
peripheral blood from five normal individuals and EBV-transformed B cell lines from six 
normal individuals,  from six patients with adult T  cell leukemia,  and from  10 patients 
with Burkitt's lymphoma were analyzed  for surface IL-2 receptor expression  by indirect 
immunofluorescent  staining  with  anti-Tac.  The  purified  B cells  were prepared  from 
normal,  heparinized  venous blood  using  Ficoli-Hypaque  (Pharmacia  Fine  Chemicals, 
Piscataway, N  J) density gradient centrifugation to isolate mononuclear cells, followed by 
centrifugal  elutriation  to  remove monocytes. The  T  cells  were removed  from  these 
lymphocyte preparations by rosette formation with neuraminidase-treated  sheep eryth- 
rocytes.  The Burkitt's lymphoma lines were established  from the involved lymph nodes 
of patients with the clinical features of Burkitt's lymphoma. Each of the lines demonstrated 
the  reciprocal  translocation  between chromosome  8  and  chromosomes  14,  2,  or  22 
characteristic  of Burkitt's lymphoma. The adult T  cell leukemia patients had circulating 
antibodies  to  the  p19  and  p24  structural  (gag)  proteins  of human  T  cell  leukemia/ 
lymphoma virus  [  (HTLV-I) (19). Four of the five  B cell  lines  examined  from these 
patients contained HTLV-I provirus integrated into thei  r genome as identified by molec- 
ular  hybridization  studies.  The  EBV-transformed,  B  cell  lines  were established  from 
normal individuals  using heparinized peripheral blood mononuclear cells depleted of T 1452  INTERLEUKIN  2  RECEPTORS  ON  B CELLS 
cells by rosetting with neuraminidase-treated sheep erythrocytes and transformed with 
EBV (culture supernatant of line B95-8). These B cell preparations contained <4%  T 
cells as defined by flow microfluorometry  after staining with Leu-4 (pan T ceil) monoclonal 
antibody. 
To induce Tac antigen expression in these freshly obtained normal purified B cells 
prepared as described above,  1 x  106 purified B cells  were co-cultured with  1 X  105 
irradiated  (2,000  rad)  T  cells and  1  X  104 irradiated (10,000  rad)  monocytes in  the 
presence of PWM (10 #g) for 6 d in RPMI 1640 media supplemented with 10% fetal calf 
serum.  At the end of the culture period, the T  cells  were removed by rosetting with 
neuraminidase-treated sheep erythrocytes, and the residual B cells were assessed  by flow 
microfluorometry for reactivity with Leu-4, Leu-10, and anti-Tac monoclonal antibodies. 
To establish Tac-positive B cell lines from normal individuals, B cells activated by the 
procedure described above were incubated with anti-Tac for 30 min and then rosetted in 
the presence of ox erythrocytes coated with an anti-mouse immunoglobulin reagent. Cells 
rosetted in this manner were separated from the nonrosetting cells  by Ficoil-Hypaque 
centrifugation and then cultured in RPMI  1640 media supplemented with 20% fetal calf 
serum in the presence of EBV (B95-8 supernatant) for 4  wk.  The resulting lines were 
then reassessed for reactivity with anti-Tac. A line (designated B22) demonstrating 25% 
reactivity with anti-Tac was cloned by limiting dilution at a density of 0.5 B cells/well in 
96-well,  round-bottom Costar plates in  the presence of 2  x  104 allogeneic, irradiated 
(5,000 rad) peripheral blood lymphocytes as a feeder layer. Two clones, 1C9 and 5B4, 
were expanded for more extensive analysis.  Both clones secreted immunoglobulin; clone 
1  C9 produced IgG~ while 5B4 produced IgMK. 
Monoelonal Antibodies.  The OKT3, T4, T8, T9, and T10 antibodies were obtained 
from Ortho Diagnostic Systems Inc., Westwood, MA. The Leu-4 and Leu-10 antibodies 
were obtained from Becton, Dickinson & Co., Mountain View, CA. The B1 and fluores- 
cein-conjugated F(ab')2 goat anti-mouse immunoglobulin antibodies were obtained from 
Coulter Electronics, Hialeah, FL. 
The preparation of the murine hybridoma-producing monoclonal anti-Tac antibody, 
an anti-I L-2 receptor antibody, has been previously described (13-15). In this study, anti- 
Tac antibody used in in vitro immunoglobulin biosynthesis experiments was purified from 
mouse ascites by DEAE cellulose (Whatman Laboratory Products, Inc., Clifton, NJ) ion 
exchange chromatography using  gradient  elution  in  Tris buffer, pH  8.0,  ranging  in 
molarity from 0.01  to 0.3 M. Anti-Tac antibody conjugated for fluorescence studies was 
purified from ascites by affinity chromatography with staphylococcal protein A-Sepharose 
(Pharmacia  Fine Chemicals) according to the  method of Ey et al.  (20).  The purified 
antibody was  conjugated to biotin succinamide (Bioresearch, San  Rafael,  CA).  Avidin 
(Pierce Chemical Co., Rockford, IL) was conjugated to fluorescein isotbiocyanate (Sigma 
Chemical Co., St.  Louis, MO) using the method of Rinderknecht (21) or to Texas Red 
(Molecular Probes, Junction City, OR) using the method of Titus et al. (22). 
Iramunofluorescence Staining.  The cells were analyzed using immunofluorescence and 
flow microfluorometry analyses by a  modification of a  procedure previously described 
(23). Cell suspensions for immunofluorescent staining were prepared in Hanks' balanced 
salt solution (without phenol red) containing 3% fetal calf serum and 0.05% sodium azide. 
For indirect one-color staining,  1 x  106 cells  were incubated for 30 min at 4°C  with 
saturating amounts of the appropriate monoclonal antibody or mouse serum as a control, 
washed twice, incubated 30 min at 4°C with fluorescein-conjugated anti-mouse immuno- 
globulin reagent, rewashed twice, and finally resuspended and analyzed for fluorescence. 
For dual fluorescence studies, cells were stained initially with biotin-conjugated anti-Tac 
antibody followed by Texas Red-conjugated avidin and then stained with fluorescein- 
conjugated antibody with appropriate washing between incubations. 
For inhibition experiments, 1 x  106 cells were incubated for 60 rain at 4°C with the 
material  being tested  for blocking activity.  Either fluorescein-conjugated antibody or 
biotin-conjugated anti-Tac antibody were then added directly to the cells with no inter- 
vening washing and incubated for 20 min at 4°C. Suspensions were then washed twice 
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conjugated avidin  before analysis  as  indicated.  Flow  microfluorometry analyses were 
performed using a  Dual Laser FACS II (B-D FACS Systems, Sunnyvale, CA) and data 
were collected and analyzed using a  PDP  11/34  computer (Digital  Equipment Corp., 
Maynard, MA) interfaced to the FACS II. Fluorescence data were collected using loga- 
rithmic amplification  on  5  ×  104  viable cells as  determined by forward light  scatter 
intensity. Data from inhibition experiments were calculated as previously described (23). 
Source of lnterleukin  2 and Polyctonal Activators.  Two preparations of IL-2, immunoaf- 
finity-purified, JURKAT-derived IL-2 and recombinant IL-2, were used in the present 
study to assure that I L-2 itself rather than any potential contaminant was the active agent. 
The procedures used to purify and characterize the JURKAT-derived IL-2 have been 
described previously (24). The IL-2 was prepared by column affinity chromatography 
using an I L-2-binding monoclonal antibody, 1  H 11-1 AS, immobilized on Sepharose 4B. 
The  bound  IL-2  was  eluted  with  1.5%  acetic acid,  pH  2.5.  When  analyzed by two- 
dimensional gel electrophoresis using silver staining for detection, the contents of the pH 
2.5 eluate migrated as a single spot. The recombinant-purified IL-2 was obtained from 
Cetus Corp., Emeryville, CA from the JURKAT IL-2 gene expressed in E. coli (25). The 
protein was 96% pure by SDS-PAGE analysis and contained <0.3 ng of LPS/1,000,000 
U of IL-2 as assessed  by the limulus amebocyte assay.  The IL-2 concentrations used in 
the present study are expressed as nanograms per milliliter. There are 0.31 U/ng of IL- 
2, where the units are those described previously by Robb and co-workers (24). One such 
unit of IL-2 activity is equivalent to 41.5 U as recently defined by the Biological Response 
Modifiers program of the National Cancer Institute. 
A  series of materials were used in the in vitro studies to activate B lymphocytes to 
synthesize and secrete immunoglobulin molecules. PWM was obtained from Gibco Lab- 
oratories, Grand Island, NY. Nocardia water-soluble mitogen (NWSM) was the kind girl 
of Dr. Constantin Bona. Wheat germ agglutinin (WGA) was obtained from Miles Labo- 
ratories, Elkhart, IN. Streptolysin-O (SLO) was obtained from Difco Laboratories, Detroit, 
MI. 
Measurement of lmmunoglobulin Synthesis by Lymphocytes Cultured In Vitro.  To study the 
effect of the anti-Tac monoclonal antibody on the differentiation of circulating B lympho- 
cytes into immunoglobulin-synthesizing and -secreting cells,  normal peripheral blood B 
cells and monocytes free of T  cells were co-cultured with autologous, irradiated (2,000 
rad) T  cells.  Polyclonal activators were added in the presence of anti-Tac or a control 
monoclonal immunoglobulin (RPC-5; Litton Bionetics, Inc., Kensington, MD) of the same 
IgG2a isotype. The B cell and T cell populations for these studies were extensively washed 
to remove serum immunoglobulins and then prepared according to techniques described 
previously (26)  using a  two-step procedure that  involves passage  of peripheral blood 
mononuclear cells through an anti-human F(ab')~  immunoabsorbent column followed by 
a rosetting step with neuramhaidase-treated sheep erythrocytes. In the biosynthesis exper- 
iment 1 x  10~B cells and 1 x  106 irradiated (2,000 rad) T  cells were co-cultured in the 
presence of optimal concentrations of PWM, WGA, SLO, or NWSM (26) for  12 d  in 
RPMI 1640 media supplemented with 10% fetal calf serum (Armour Pharmaceutical Co., 
Phoenix, AZ),  2  mM  L-glutamine (Gibco  Laboratories), and  50  #g/mi  penicillin  and 
streptomycin solution (Gibco Laboratories). 
Scatchard  Analysis  of 3H-Anti-Tac Binding  to  Tac-positive B  Cell Lines.  To estimate 
receptor number and ligand affinity, purified anti-Tac was tritiated to high specific activity 
by reductive methylation (910  Ci/mmol) (27).  Cell  populations to be examined were 
washed three to four times in balanced salt solution and suspended at 20 x  108 viable 
cells/ml in binding medium [RPMI  1640,  1% bovine serum albumin  (Sigma Chemical 
Co.), 1 mg/ml human IgG (Cutter), 25 mM Hepes (Gibco Laboratories), and 0.1% sodium 
azide (Sigma Chemical Co.)]. Aliquots of 106 cells were incubated with labeled antibody 
(1-11 ng, depending on the assay) for 45 rain at room temperature in the presence of 
graded amounts (0-1,600 ng) of unlabeled anti-Tac in a final volume of 90-200 #1 in 1.5- 
ml Eppendorf tubes. Cell-associated and free radiolabeled antibodies were separated by 
centrifuging the reaction mixture through 750-t~1 cushions of binding medium containing 
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salt solution and tranferred to glass vials for liquid scintillation counting. Specific binding 
was determined by incubating cells and labeled antibody with a >l,000-fold excess of 
unlabeled anti-Tac,  generally 28  #g.  Scatchard analyses (28,  29)  were  performed by 
plotting the values for bound/free vs. bound radioactivity. 
Radiolabeted IL-2-binding  Assay.  Biosynthetically radiolabeled human  IL-2 was  pre- 
pared by stimulation of JURKAT cells (4 ×  106/ml)  in serum-free Dulbecco's modified 
Eagle's medium containing 40 #M unlabeled leucine, 65 #M unlabeled lysine, 0.5 mCi/ 
ml of [3H]leucine (52 Ci/mmol; ICN Nutritional Biochemicals, Cleveland, OH), 0.5 mCi/ 
ml [3H]lysine (39 Ci/mmol), 1.5 #g/ml phytohemagglutinin (HA-16; Weilcome Reagents), 
and 50 ng/ml phorboi-12-myristic-13-acetate (Consolidated Midlands Corp.) (12).  After 
16 h at 37 ° C, the cell supernatant was harvested and the radiolabeled I L-2 was extracted 
by immunoaffinity chromatography (24). The labeled IL-2 (23 x  106 dpm/#g) migrated 
as a single band at 15,500 Mr on SDS-PAGE. 
The  level  and  affinity of [~H]IL-2  binding  to  cells  was  determined  as  previously 
described (12) by incubating a  known quantity of cells  (0.5  to  1.5  x  106) with  serial 
dilutions of [SH]IL-2 in RPMI  1640,  I0 mg]ml bovine serum albumin, 25 mM Hepes, 
pH 7.2 (RPMI-BSA), in a final volume of 0.1  ml. After 20 min at 37°C, the cells were 
washed twice with ice-cold RPMI-BSA and centrifuged through a  400-#1 layer of 85% 
silicon oil/15% paraffin oil. The tip of the tube containing the cell pellet was transferred 
to a  scintillation  vial  where  the  cells  were  suspended  in  200  #1  PBS,  then  lysed and 
dissolved by the addition of 200 #1 1% SDS. 
Structure of Receptor on B Cells Identified by Anti-Tac.  10-20 x  106 cells were incubated 
and biosynthetically labeled for 18 b with 250-500 #Ci of [~H]D-glucosamine  (32.5 Ci/ 
mmol; New England Nuclear, Boston, MA).  Cells were then washed and solubilized for 
30-60 rain at 4°C in 0.14 M NaCI,  1% Triton X-100, 10 mM Tris HCI (pH 7.4), and 50 
#g/ml phenylmethylsulfonyl  fluoride. Nuclei and cell debris were removed by centrifuga- 
tion (12,000 g for 15 min) and the supernatants immunoprecipitated with anti-Tac and 
Cowan I strain staphylococci as previously described (15, 30).  Immunoprecipitates were 
analyzed by 8.75% SDS-PAGE performed under reducing conditions. Gels were enhanced 
(Enlightning; New England Nuclear), dried under vacuum, and analyzed after fluorog- 
raphy. In parallel studies, surface proteins of the B cell lines were labeled by lactoperoxi- 
dase-catalyzed iodination. ~5-10  x  106 cells  were washed and suspended in  100 #1 of 
balanced salt solution and 1 mCi of carrier-free Nal~SI was added. 4 #1 of lactoperoxidase 
solution (100 U/ml) and 7.5 #1 of H202 solution (0.03%) were then added and the cells 
incubated for 4 min at room temperature. An additional 2 #1 of lactoperoxidase solution 
and 7.5 #i of H~O2 were then added and cells incubated for an additional 4 min. Cells 
were then washed in balanced salt solution and immunoprecipitated as described above. 
Results 
Anti-Tac Inhibits Helper T Cell-dependent Immunoglobulin Synthesis.  The ability 
of anti-Tac  to  inhibit  helper  T  cell-dependent  immunoglobulin  synthesis  by 
normal B  cells was evaluated using an in vitro biosynthesis system.  B  cells and 
irradiated (2,000 rad) T  cells isolated from normal  individuals were combined 
and cultured at 5  X  105 cells/ml for  12 d  with PWM,  WGA, SLO, or NWSM. 
The immunoglobulins synthesized and secreted into the media during the  12-d 
culture period were assayed using sensitive double antibody radioimmunoassays 
for IgM,  IgG, and  IgA (31,  32). The geometric mean values for IgM synthesis 
by B  and  T  cells from  10  normal  individuals  after stimulation  for  12  d  with 
PWM, WGA, SLO, and NWSM were 4,180 (1.4)  ~ ng, 7,950 (2.5) ng, 7,612 (1.6) 
ng, and 3,879 (1.5) ng, respectively, per  10  6 cells in  1-mi cultures. Purified anti- 
Tac, when added at a final concentration of 2 #g/ml, inhibited IgM synthesis by 
57, 64, 47, and 53% for cultures stimulated by PWM, WGA, SLO, and NWSM, 
2 Standard error of the log of geometric mean. WALDMANN  ET  AL.  1455 
respectively (Fig.  1). Anti-Tac also comparably inhibited IgG and IgA synthesis 
(data not shown). A  control monoclonal antibody (RPC-5) of the same isotype 
(IgG2a) as anti-Tac did not inhibit the immunoglobulin synthesis induced by 
these stimulants (Fig.  1). The suppression of immunoglobulin biosynthesis by 2 
t~g of anti-Tac was overcome by the addition of 50  ng of purified JURKAT- 
derived I L-2 to the biosynthesis system, supporting the view that anti-Tac inhibits 
through binding to the IL-2  receptor.  However, the maturation of B cells to 
immunoglobulin-synthesizing cells requires the participation  of helper T  cells 
with the polyclonal activators used (32).  Thus, the site of action of anti-Tac in 
this system cannot be completely defined; both an effect on T  cells to inhibit 
their secretion of B cell growth and differentiation factors or a direct action at 
the B cell level are possible. 
Interleukin 2  Receptors on B  Cells.  For anti-Tac to act directly on B cells, the 
B cells would be expected to display the Tac antigen (i.e., IL-2 receptors). To 
determine whether B cells manifest IL-2  receptors, purified B cells from five 
normal individuals and from individuals with B cell leukemias were examined by 
indirect immunofluorescence using anti-Tac. Anti-Tac did not react with rigor- 
ously purified resting normal B cells (Fig. 2). Furthermore, five of six unselected 
B cell lines from normal individuals, established using EBV, were Tac antigen 
negative. In contrast, the Tac antigen was demonstrable on the cell surface of 6 
of 10 B cell lines derived from patients with Burkitt's lymphoma and on 5 of 6 
EBV-transformed B cell lines from patients with human T  cell leukemia/lym- 
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FIGURE  1.  Effects of the addition  of monoclonal anti-Tac or control  monoclonal  RPC-5 
antibodies on ]gM synthesis and secretion of cultured normal B and irradiated (2,000 rad) T 
cells stimulated by pokeweed mitogen (PWM), wheat germ agglutinin (WGA), streptolysin-O 
(SLO), and Nocardia water-soluble mitogen (NWSM). Purified anti-Tac, when added at a final 
concentration of 2  izg/ml, inhibited polyclonal IgM synthesis by 47-64%,  whereas control 
RPC-5 monoclona[ antibody did not inhibit immunoglobulin synthesis. 1456  INTERLEUKIN  2  RECEPTORS  ON  B  CELLS 
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FIGURE 2.  Activated B cells from patients with certain lymphoid malignancies manifest IL-2 
receptors identified by the anti-Tac monoclonal antibody. The percent of Tac-positive B cells 
are plotted for individuals with different disease states. The purified B cell populations were 
analyzed by indirect immunofluorescence flow microfluorometric analysis with anti-Tac and 
fluorescein-conjugated anti-mouse antibody reagents. 
phoma  virus-associated adult T  cell leukemia.  None of the  B cell populations 
exhibiting  anti-Tac  reactivity  by indirect  fluorescence  were  reactive  with  the 
control  monoclonal  RPC-5 antibody or with  the  Leu-4 antibody,  which reacts 
with virtually all mature T  cells. 
Although  normal  resting  B  cells and  the  majority of unselected  EBV-trans- 
formed B cell lines from normal individuals were Tac antigen negative, we next 
demonstrated that  Tac antigen  expression can be induced with normal  B cells. 
Furthermore,  we have successfully established cloned normal  B  cell  lines  that 
express  Tac  antigen.  Populations  of  1  ×  106  purified  B  cells  from  normal 
individuals and  1 x  105 autologous (irradiated at 2,000 rad) T  cells and  1 x  104 
irradiated (1,000 rad) monocytes were stimulated with PWM for 6 d. At the end 
of the culture period the T  lymphocytes were removed by a neuraminidase sheep 
erythrocyte rosetting procedure. The residual population of B lymphocytes were 
Leu-4 negative,  Leu-10 positive, yet contained a  proportion  (21-43%) of Tac- 
positive cells, as evaluated by indirect  immunofluorescence.  Thus,  normal  pri- 
mary B cells could be induced to display the Tac antigen after PWM activation WALDMANN  ET  AL.  1457 
in the presence of T  cells. To establish Tac-positive B cell lines, the activated B 
cells were incubated with the anti-Tac  monoclonal antibody and then  rosetted 
in the presence of ox erythrocytes coated with an antibody to mouse immuno- 
globulin. Rosetted Tac-positive B cells were cultured in the presence of EBV for 
4 wk. 5-39% of the cells in 9 of the 10 EBV-transformed B cell lines established 
by this method were Tac positive. Cloned lines were established from one of the 
Tac-positive B cell lines, B22, by limiting dilution at a density of 0.5 B cells/well. 
Two of the cloned lines,  1  C9,  which constitutively expressed the Tac antigen, 
and 5B4, which could be induced to express Tac antigen, were further studied. 
Both the original  line B22 and the cloned daughter lines  1C9 and induced 5B4 
contained  a  proportion  of Tac-positive  cells  identified  by  microfluorometric 
analysis when they were stained with biotinylated anti-Tac  and then  incubated 
with fluoresceinated avidin.  The cloned lines were not reactive with the mono- 
cional  antibodies  Leu-4,  T4,  T8,  3A-l,  and  T-11,  which  react  with  T  cells. 
Furthermore,  the Tac-positive cells also displayed surface immunoglobulin and 
the Leu-10 antigen characteristic of B cells when assessed by two-color fluores- 
cence studies.  The addition of 500 ng of purified  IL-2, derived from induced 
JURKAT leukemic cells, blocked the binding of anti-Tac  to these lines (Table 
I). In contrast, the addition of 5,000 ng of IgM to the incubation system did not 
block the binding of anti-Tac to its receptor on line B22 although it blocked the 
binding of fluoresceinated anti-IgM to this line (Table I). 
The binding of 3H-anti-Tac to line  1  C9 was examined by Scatchard analysis 
as shown in Fig. 3. Approximately 7.4 ×  10 s antibody molecules were bound per 
cell with an apparent Kd of 1.04 ×  10  -l° M. In parallel studies using biosynthet- 
ically labeled IL-2 (JURKAT), line  1  C9 expressed -1,400 high affinity (Kd, 2.7 
×  10 -1~  M) IL-2 binding sites per cell (average for the entire population in six 
experiments).  Furthermore,  binding of the [3H]IL-2 to  1C9 cells was inhibited 
by the anti-Tac antibody, demonstrating  that, as on activated T  cells, the IL-2- 
binding sites contain the Tac protein. These findings support the conclusion that 
normal B cells can be activated to express receptors for IL-2. 
Induction of lL-2 Receptors on a Normal B Cell Line by IL-2.  The cloned normal 
B cell line  5B4 prepared as described above manifested only small numbers of 
cell surface molecules identified by anti-Tac.  5% of these cells were Tac positive 
by flow microfluorometry and displayed only 520 Tac molecules per cell (average 
for the entire  population) as determined  by Scatchard  analysis of 3H-anti-Tac 
TABLE  I 
Inhibition  of Binding of Anti-Tac on the B Cell Line, B22, by Purified 
JURKAT IL-2 Assessed by Flow Cytometry 
Inhibitor added  Inhibition of  Inhibition  of 
anti-Tac binding  anti-human  IgM 
binding 
%  % 
IL-2 (500 ng)  100  7 
IL-2 (50 ng)  47  8 
IL-2 (5 ng)  38  14 
Human IgM (5,000 ng)  15  97 1458  INTERLEUKIN  2  RECEPTORS  ON  B  CELLS 
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FIGURE 3.  Scatchard analysis of SH-anti-Tac binding to a cloned normal B cell line. SH-anti- 
Tac binding was performed as described in the Materials and Methods section. Transformation 
of binding data indicated that 1  C9 cells displayed ~7,400 receptors per cell with an apparent 
Ka of 1.04 x  10  -'° M. 
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FIGURE 4.  Purified IL-2 induces augmented IL-2 receptor expression in cloned normal B 
cell line 5B4. Binding of anti-Tac or RPC-5 was measured by flow microfluorometry analysis 
of  fluorescence  intensity  generated  by  reacting  different  cell  populations  with  antibody 
conjugated  to  biotin  succinimide  and  subsequently  with  avidin  conjugated  to  fluorescein 
isothiocyanate. Before flow microfluorometric analysis induced 5B4 cells bad been incubated 
for 48 h with 50 ng/ml of immunoaffinity-purifiedJURKAT IL-2. 
binding. The ability of this population to be induced to express larger numbers 
of Tac receptors was explored after an initial observation that exposure of this 
line for 48  h  to iectin-depleted conditioned medium containing IL-2 led to an 
increase in the proportion of Tac-positive cells  from 5 to >30%.  The addition 
of either immunoaffinity-purified  JURKAT  IL-2 or  recombinant IL-2  to  the 
culture in the range of 10-100 ng/106 cells increased the receptor number from 
520 to 4,500 per cell after 48 h of culture (Figs.  4-6). The addition of 1 ng/ml 
purified JURKAT IL-2 led to an intermediate 50%  increase in the number of 
receptors  per  cells.  This  concentration (6  x  10  -ll  M)  required  for one-half- 
maximal  induction  is  comparable  to  the  Kd  (2.7  X  10 -~  M)  for  binding  of 
[3H]IL-2 to ks receptor on the cloned B cell line. An increase in specific binding 
was seen as early as 12 h after exposure to the purifiedJURKAT IL-2 preparation 
and reached a maximum at 48 h (Fig. 5). The Kd for binding of 3H-anti-Tac to WALDMANN  ET  AL. 
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FIGURE 5.  Time course of 1L-2 induction of Tac antigen expression on 5B4 cells. Specific 
binding of SH-anti-Tac is plotted as a function of the time ofJURKAT IL-2 induction of 5B4 
cells cultured with 50 ng/ml purified IL-2. 
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FIGURE 6.  IL-2 induction of 5B4 cells increases the binding of 3H-anti-Tac. Uninduced 5B4 
line bound 0.13 ng of 3H-anti-Tac/106 cells, indicating an average of 520 receptors per cell 
whereas 5B4 cells incubated with 50 ng of purified JURKAT IL-2 for 48 h bound 1.12 ng of 
anti-Tac/I 06 cells indicating an average of 4,500 receptors per cell with an apparent Kd of 
1.14 ×  10  -1° M. 
the  induced  cell  population  was  1.14  x  10 -]°  M  (Fig.  6).  The  addition  of 
cycloheximide (5  x  10 -6  M)  abrogated  the  increase  in  IL-2  receptors  after 
exposure to purified IL-2. The concentration of cycloheximide used blocked aH- 
leucine incorporation  by  90%,  but  did  not  produce immediate cell  death  as 
assessed by trypan blue dye exclusion. Furthermore, actinomycin D (3 X 10 -7 M 
and  3  x  10 -8  M)  produced >95%  inhibition  of IL-2  receptor induction.  In 
contrast, inhibition  of DNA synthesis by irradiation (2,000,  4,000,  and 8,000 
tad)  sufficient to  inhibit  thymidine uptake  by  85%  did not  inhibit  the  IL-2- 
induced IL-2 receptor expression. With the 4,000 rad dose of irradiation, there 
was only a modest reduction in cell viability, with 91% of the cells still excluding 
trypan blue. Thus, the induction of IL-2 receptor expression after exposure of 1460  INTERLEUKIN 2  RECEPTORS  ON  13  CELLS 
FIGURE 7.  Size of IL-2 receptors on cloned normal B cell lines 1C9 and 5B4. (A) 1C9 cells 
were biosynthetically  labeled with [SH]n-glucosamine for 18 h solubilized in non-ionic deter- 
gent and immunoprecipitated with anti-Tac (lane A) or control UPC-10 antibody (lane B) as 
previously  described (15). Immunoprecipitates were analyzed by SDS-PAGE on 8.75%  gels 
performed under reducing conditions.  Migration of known molecular weight markers is shown. 
(B) The 5B4 cell line and activated  T  cells were surface  iodinated  and analyzed as in A. No 
radiolabeled  proteins were precipitated by UPC-10 from uninduced (lane A) or induced (lane 
B)  5B4 cells. Anti-Tac immunoprecipitated a faint  band from uninduced 5B4 cells (lane C) 
and a much more intense  band from 5B4 cells induced for 48 h with 50 ng/ml of  JURKAT 
IL-2 (lane D). Anti-Tac immunoprecipitation of  surface-labeled, PHA-activated T lymphoblasts 
is shown in lane E. 
the  5B4  line  to  IL-2 requires  RNA  transcription  and  protein  synthesis  but  not 
DNA replication. 
Structure oflL-2 Receptors on B Cells.  On the basis of our previous studies (15, 
31),  the  Tac  antigen  (IL-2  receptor)  present  on  activated  normal  T  cells  was 
shown to be a  glycoprotein with  an Mr of 53,000-57,000.  The  Tac antigen  on 
cloned  normal  B  cell  line  1C9,  biosynthetically  labeled  with  [3H]~glucosamine 
and  immunoprecipitated  with  anti-Tac  but  not  control  UPC-10  antibody,  was 
similar  in  size to the  receptor  on  T  cells  (Fig.  7A).  In addition,  the  size of the 
Tac antigen  on 5B4 cells induced with  IL-2 and labeled  with  1~5I was similar  in 
size  to  the  receptor  precipitated  by  anti-Tac  on  simultaneously  studied  PHA- 
stimulated  T  cell iymphoblasts (Fig.  7B). 
Functional Effects of lL-2 and Anti-Tac on  the B  Cell Line 5B4.  The  synthesis WALDMANN ET  AL. 
TABLE II 
The Effect of Purified JURKAT IL-2 and Anti-Tac on 
lramunoglobulin  Synthesis by Line 5B4 
Growth factor added 
Immunoglobulin 
Monoclonal antibody  synthesized  by 
10  6 5B4 cells in  added  culture 
for 14d 
ng 
1. None  None  2,790 
2. IL-2 (100 ng)  None  10,754 
3. IL-2 (20 ng)  None  9,323 
4. None  Anti-Tac (20 #g)  3,629 
5. None  RPC-5 (20 #g)  3,842 
6. IL-2 (20 ng)  Anti-Tac (20 ~g)  3,015 
7. IL-2 (20 ng)  RPC-5 (20 ~g)  7,137 
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and  secretion  of IgM  into the  media in  these  cultures was  increased  two-  to 
fourfold by the addition of 1,  10,  20, 50, or 100 ng of purifiedJURKAT IL-2/ 
10 6 5B4 cells per milliliter ml in culture (Table II). This IL-2-inducible compo- 
nent of IgM synthesis was completely blocked by the addition of 20 #g of anti- 
Tac. In contrast, the addition of the control monoclonal (RPC-5) did not alter 
I L-2-stimulated immunoglobulin synthesis. Furthermore, the addition of various 
concentrations of purified JURKAT IL-2 or anti-Tac had no effect on the cell 
number at the termination of the culture or the proliferation ([3H]thymidine 
uptake) of 5B4 cells, either when added before or after induction of IL-2 receptor 
expression (data not shown). Thus, IL-2 did not alter the rate of proliferation of 
the  5B4  line,  but  appeared  to  facilitate the  terminal differentiation of these 
cloned normal B cells into immunoglobulin-synthesizing  and -secreting cells. 
Discussion 
IL-2 Receptor  Expression  on Activated  B  Cells.  In previous reports (4,  12),  no 
receptors for IL-2 were demonstrated on resting B cells  or on the activated B 
cells examined.  These activated B  cells include  LPS-stimulated mouse spleen 
cells as well as the Burkitt lines Raji and Daudi. In this report, we demonstrate 
that some activated B cells express membrane receptors for IL-2.  Monoclonal 
anti-Tac, which identifies the human receptor for IL-2, binds to certain malignant 
B cell populations including 6 of 10 patients with Burkitt's lymphoma, and the 
B cell lines derived from 5 of 6 patients with the HTLV-I-associated adult T  cell 
leukemia. Furthermore, B cells from normal individuals activated by PWM in 
the presence of T  cells expressed the Tac antigen.  In addition, cloned EBV- 
transformed B  cell  lines  derived  from  Tac-positive  activated  normal  B  cells 
continued to express Tac antigen in long-term cultures. The binding of anti-Tac 
to  B  cells  rather  than  T  cells  in  each  of these  systems  was  confirmed  by 
demonstrating that the purified cells and cell lines examined did not react with 
Leu-4 and that the Tac-positive cells assessed by two-color fluorescence analysis 
concomitantly expressed the B cell-associated antigen identified by the monocio- 
nal  antibody Leu-10.  Furthermore,  both  immunoaffinity-purified, JURKAT- 1462  INTERLEUKIN 2  RECEPTORS ON  B CELLS 
derived IL-2 and recombinant IL-2 blocked the binding of anti-Tac to the Tac- 
positive  B  cell  lines.  In  addition,  -1,400  high  affinity  IL-2  receptors  were 
detectable on  1C9 cells when studied with purified  radiolabeled  IL-2.  Finally, 
the  size  of the  receptor  identified  by anti-Tac  on  B  cells  was similar  to  that 
present on activated T  cells. These data are in accord with the view that some 
activated B cells express membrane receptors for IL-2. 
There are possible explanations  for the discordance between this conclusion 
and the view expressed in previous studies that B cells do not bear IL-2 receptors. 
We have shown that the Burkitt's lymphoma line studied previously, the Daudi 
line (12),  which  was reported  to be  IL-2  receptor  negative,  is also unreactive 
with anti-Tac.  Furthermore,  the level of Tac antigen expression on activated B 
cells is 5-10-fold less than that characteristic of activated T  cells (33).  Even the 
Tac-positive B cell lines,  1  C9 and induced 5B4, which have the most receptors 
we  have  observed on  normal  B  cells,  manifested  only  7,500  and  4,500  Tac 
receptors, respectively, as assessed by Scatchard analysis of 3H-anti-Tac binding, 
whereas PHA-activated T  cells expressed 30,000-60,000 receptors per cell, and 
HTLV-positive adult  T  cell  leukemia T  cell  lines such as HUT102 expressed 
150,000-600,000 Tac receptors per cell (33). Thus, the number of high affinity 
IL-2 receptors on the activated B cells studied previously may have been too low 
to  be  detected  by some of the  techniques  used.  Taken  as  a  whole,  the  data 
support  the  hypothesis  that  IL-2  receptors  are  induced  on  some  but  not  all 
activated B cell populations. 
IL-2 Induction  of IL-2  Receptors  on  B  Cells.  The  line  5B4  reported  in  the 
present  study  can  be  induced  with  IL-2  to  express  augmented  numbers  of 
receptors identified  by the anti-Tac  antibody (an  increase from  520  to 4,500 
receptors per cell). These studies suggest that IL-2 may up-regulate the number 
of IL-2 receptors expressed by this B cell line. The fact that both immunopurified 
JURKAT IL-2 and recombinant  IL-2 could augment  receptor expression sug- 
gests that IL-2 itself rather than any potential contaminant was the active agent. 
The requirements for RNA transcription  and protein synthesis suggests that de 
novo receptor synthesis is occurring rather than the unmasking of cryptic recep- 
tors. The view that IL-2 induces cells with low numbers of receptors to synthesize 
and express high numbers of cell surface IL-2 receptors rather than causing the 
outgrowth of cells with high numbers of receptors is supported by the observa- 
tions that the Tac receptors were induced within 12-24 h and that this induction 
was not inhibited by doses of gamma irradiation  that profoundly inhibited DNA 
synthesis.  Although  in many receptor-ligand systems the addition of the ligand 
leads to down-regulation  of the receptor numbers,  there is precedence for up- 
regulation of the number of surface receptors by certain ligands.  For example, 
surface Fc epsiion receptors were induced on activated T  cells after the addition 
of IgE  (34).  Similarly,  Fc alpha  receptors were induced  on T  lymphocytes by 
addition of IgA to in vitro cultures of these cells (35). Furthermore, an increase 
in the number of insulin receptors was observed with 3T3 (36) and chondrosar- 
coma cell lines (37) in response to insulin.  In  3T3 cells this induction was slow 
and  was  paralleled  by  the  maturation  of  the  3T3  cells  into  more  mature 
adipocytes (36). In the case of the chondrosarcoma cells there was no change in 
apparent  state of maturation  or phenotype of the  cells (37).  With  the  present WALDMANN  ET  AL.  1463 
line,  5B4,  there was no change in  the proportion of cells that reacted with a 
series of monoclonal antibodies including B1, B2, T9, and BA1. Since the line 
5B4  is an  EBV-transformed line that does not require exogenous IL-2  for its 
proliferation, it provides a valuable line for the study of the factors involved in 
the induction of IL-2 receptors on B lymphocytes. 
Functional Role of lL-2 in B Cell Differentiation.  Although it appears that IL- 
2  receptors develop on  certain  B  cells during their activation,  the functional 
significance of the interaction of IL-2 with this receptor is not clear. It is evident, 
for example, in studies of Tac-negative, EBV-transformed B cell lines that this 
interaction is not absolutely required for immunoglobulin synthesis, nor is the 
addition of IL-2 alone to B cells sufficient for B cell proliferation or differentia- 
tion.  Furthermore, it is conceivable that the IL-2 binding receptors on B cells 
that we have identified might also be receptors for another B  cell growth or 
differentiation factor.  However, the  high affinity (Kd, 2.7  X  10 -LI  M) of the 
binding of IL-2 to these receptors on B cells would be more in line with primary 
specificity for IL-2 rather than for some other ligand. 
Anti-Tac inhibited polyclonal immunoglobulin biosynthesis in response to the 
helper T  cell-dependent polyclonal activators, PWM, SLO, NWSM, and WGA. 
However, in these cases, the effect could either be on the B cells directly or on 
the production of B cell growth and differentiation factors by T  cells. Howard 
and co-workers (38) have indeed demonstrated the requirement for IL-2 for the 
synthesis of B cell growth factor by T  cells. However, IL-2  may have a  more 
direct effect on  B  cells as well.  In additional studies we have shown that  the 
immunoglobulin biosynthesis response of rigorously T  cell-depleted B cells to a 
crude T  cell-replacing factor (the supernatants of T  cells stimulated by PWM) 
was abrogated by the addition of 20 vg of anti-Tac. The B cells utilized in this 
latter study were prepared by adherence to anti-immunoglobulin columns fol- 
lowed by removal of any residual T  cells by rosetting with neuraminidase-treated 
sheep erythrocytes  and did not proliferate to T cell-mitogens. Furthermore, they 
did not synthesize immunoglobulins when stimulated with PWM. However, these 
B cells synthesized IgM, IgG, and IgA when cultured with the supernatants of T 
cells cultured for 48 h with PWM. This TRF-stimulated synthesis was abrogated 
when 20 ~g of anti-Tac was added. 
To avoid any potential effects of anti-Tac on such contaminating T  cells that 
might be present in any preparation of freshly obtained mononuclear cells, we 
have also studied the effect of anti-Tac on immunoglobulin synthesis by a cloned 
B cell line from a normal individual, line 5B4. Immunoglobulin synthesis by this 
line was increased two- to fourfold by the addition of purified IL-2 in the absence 
of a  concomitant increase  in  cell  number.  This  increase  in  immunoglobulin 
synthesis could be completely blocked by the addition of anti-Tac (Table  II). 
Augmentation of immunoglobulin synthesis in conjunction with the observation 
that neither IL-2 nor anti-Tac affected DNA replication by these B cells suggests 
that IL-2  can facilitate the terminal differentiation of B cells. Clearly, further 
studies are required to  address the significance of the role  of IL-2  in  B  cell 
proliferation and differentiation. However, these observations, taken in conjunc- 
tion  with  studies  summarized  by  Howard  and  Paul  (9),  would  support  the 
following model of B  cell activation,  growth,  and differentiation: B  cells are 1464  INTERLEUKIN  2  RECEPTORS  ON  B  CELLS 
activated by the binding of appropriately presented antigen to its specific recep- 
tor,  cell  surface  immunoglobulin.  B  cell  activation  progresses and  the  B  cells 
enter a proliferative cycle after the interaction of IL-1 and BCGF with receptors 
for these ligands that appear on the B cell surface. The terminal  maturation  of 
these proliferating B cells involves the binding of a series of antigen-nonspecific 
B cell differentiation  factors and,  in certain  cases,  IL-2 with specific receptors 
inducibly expressed on the activated proliferating  cells. Thus,  IL-2 would join 
other antigen-nonspecific factors produced by T  cells as a potential regulator of 
the  differentiation  of B  cells into  immunoglobulin-synthesizing  and  -secreting 
cells. 
Summary 
Using anti-Tac, a monoclonal anti-interleukin  2 (IL-2) receptor antibody, we 
have explored the possibility that certain activated B cells display receptors for 
IL-2. Resting normal B cells and unselected B cell lines established from normal 
individuals were Tac antigen negative. In contrast,  the cell surface Tac antigen 
expression was demonstrable on 6 of 10 B cell lines from patients with Burkitt's 
lymphoma,  5  of 6  B  cell  lines  derived  from  patients  with  HTLV-I-associated 
adult T  cell leukemia (including all four that had integrated HTLV-I into their 
genome),  and  on  certain  normal  B  cells  activated  with  pokeweed  mitogen. 
Furthermore,  cloned Epstein-Barr  virus-transformed  B cell lines derived from 
Tac-positive normal  B cells continued  to express the Tac antigen  in  long-term 
cultures and manifested high affinity IL-2 receptors identified in binding studies 
with purified  radiolabeled  IL-2.  The  line  5B4 developed in  the present  study 
could be induced with purifiedJURKAT-derived or recombinant IL-2 to express 
a larger number of IL-2 receptors. Furthermore, the addition of IL-2 to the 5B4 
B cell line augmented IgM synthesis, which could be blocked by the addition of 
anti-Tac.  The size of the IL-2 receptors expressed on the cloned normal B cell 
lines was similar (53,000-57,000  daltons) to that  of receptors on phytohemag- 
glutinin-stimulated  T  cell lymphoblasts.  Thus,  certain  malignant  and activated 
normal B cells display the Tac antigen and manifest high affinity receptors for 
IL-2.  These  data  suggest  that  IL-2  may  play a  role  in  the  differentiation  of 
activated B cells into immunoglobulin-synthesizing and -secreting cells. 
We express our thanks  to David Stephany for performing many of the flow microfluoro- 
metry experiments. 
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